Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication

References

• NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. J. Am. Med. Assoc. 272, 65–69 (1994).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection – the Maastricht 2–2000 Consensus Report. Aliment. Pharmacol. Ther. 16, 167–180 (2002).
   PubMed Web of Science ®Google Scholar
• Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 18, 647–654 (2003).
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection – a meta-analysis. Aliment. Pharmacol. Ther. 13, 857–864 (1999).
   PubMed Web of Science ®Google Scholar
• Calvet X, Garcia N, Lopez T et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther. 14, 603–609 (2000).
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Hennessy TW, Bensler JM et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann. Intern. Med. 139, 463–469 (2003).
   PubMed Web of Science ®Google Scholar
• Branca G, Spanu T, Cammarota G et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int. J. Antimicrob. Agents 24, 433–438 (2004).
   PubMed Web of Science ®Google Scholar
• Perri F, Festa V, Merla A et al. Randomized study of different ‘second-line’ therapies for Helicobacter pylori infection after failure of the standard ‘Maastricht triple therapy’. Aliment. Pharmacol. Ther. 18, 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Wong WM, Gu Q, Lam SK et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 17, 553–560 (2003).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gisbert JL, Marcos S et al. Seven-day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment. Pharmacol. Ther. 13, 1311–1316 (1999).
   PubMed Web of Science ®Google Scholar
• Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple ‘rescue therapy’ vs. quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole. Aliment. Pharmacol. Ther. 16, 1277–1282 (2002).
   PubMedGoogle Scholar
• Boixeda D, Bermejo F, Martin-De-Argila C et al. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 16, 1457–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Gomollon F, Ducons JA, Ferrero M et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 4, 222–225 (1999).
   PubMed Web of Science ®Google Scholar
• Peitz U, Sulliga M, Wolle K et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment. Pharmacol. Ther. 16, 315–324 (2002).
   PubMed Web of Science ®Google Scholar
• Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J. Clin. Gastroenterol. 31, 222–225 (2000).
   PubMed Web of Science ®Google Scholar
• Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication ‘rescue therapy’. Aliment. Pharmacol. Ther. 15, 143 (2001).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X, Bujanda L et al. ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 8, 90–94 (2003).
   PubMed Web of Science ®Google Scholar
• Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens. Aliment. Pharmacol. Ther. 14, 311–316 (2000).
   PubMed Web of Science ®Google Scholar
• Perri F, Festa V, Clemente R et al. Randomized study of two ‘rescue’ therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. 96, 58–62 (2001).
   PubMed Web of Science ®Google Scholar
• Qasim A, Sebastian S, Thornton O et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment. Pharmacol. Ther. 21, 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• Coelho LG, Moretzsohn LD, Vieira WL et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment. Pharmacol. Ther. 21, 783–787 (2005).
   PubMed Web of Science ®Google Scholar
• Sotoudehmanesh R, Malekzadeh R, Vahedi H et al. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion 64, 222–225 (2001).
   PubMed Web of Science ®Google Scholar
• Wong WM, Wong BC, Lu H et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment. Pharmacol. Ther. 16, 793–798 (2002).
   PubMed Web of Science ®Google Scholar
• Cheon JH, Kim N, Lee DH et al. Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Korean J. Gastroenterol. 45, 111–117 (2005).
   PubMedGoogle Scholar
• Bilardi C, Dulbecco P, Zentilin P et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin. Gastroenterol. Hepatol. 2, 997–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Nista EC, Candelli M, Cremonini F et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment. Pharmacol. Ther. 18, 627–633 (2003).
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Aoyama N, Shirasaka D et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig. Liver Dis. 35, 711–715 (2003).
   PubMedGoogle Scholar
• Zullo A, Hassan C, De Francesco V et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig. Liver Dis. 35, 232–236 (2003).
   PubMedGoogle Scholar
• Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment. Pharmacol. Ther. 13(Suppl. 3), 3–10 (1999).
   PubMedGoogle Scholar
• Fujisaki H, Oketani K, Shibata H et al. Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro. Nippon Yakurigaku Zasshi 102, 389–397 (1993).
   PubMedGoogle Scholar
• Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 272, 22438–22446 (1997).
   PubMed Web of Science ®Google Scholar
• Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther. 17, 1507–1514 (2003).
   PubMed Web of Science ®Google Scholar
• Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 12, 1079–1089 (1998).
   PubMed Web of Science ®Google Scholar
• Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br. J. Clin. Pharmacol. 36, 467–469 (1993).
   PubMed Web of Science ®Google Scholar
• Gardner JD, Perdomo C, Sloan S et al. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 16, 455–464 (2002).
   PubMedGoogle Scholar
• Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. 98, 2616–2620 (2003).
   PubMed Web of Science ®Google Scholar
• Adachi K, Hashimoto T, Hamamoto N et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J. Gastroenterol. Hepatol. 18, 1392–1398 (2003).
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. 38, 243–270 (2000).
   PubMed Web of Science ®Google Scholar
• Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin. Pharmacol. Toxicol. 95, 2–8 (2004).
   PubMed Web of Science ®Google Scholar
• Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12, 415–416 (1990).
   PubMed Web of Science ®Google Scholar
• Balian JD, Sukhova N, Harris JW et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther. 57, 662–669 (1995).
   PubMed Web of Science ®Google Scholar
• Chiba K, Kobayashi K, Manabe K et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4´-hydroxylation. J. Pharmacol. Exp. Ther. 266, 52–59 (1993).
   PubMed Web of Science ®Google Scholar
• Johnson D, Perdomo C, Barth J, Jokubaitis L. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor. Eur. J. Gastroenterol. Hepatol. 12, 799–806 (2000).
   PubMedGoogle Scholar
• He LH, Yin Y, You YH, Yan XM, Zhang JZ. In vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori. Zhonghua Liu Xing Bing Xue Za Zhi 24, 447–448 (2003).
   PubMedGoogle Scholar
• Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 44, 458–461 (2000).
   PubMed Web of Science ®Google Scholar
• Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol. Pharm. Bull. 18, 1053–1056 (1995).
   PubMed Web of Science ®Google Scholar
• Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol. Pharm. Bull. 19, 182–187 (1996).
   PubMed Web of Science ®Google Scholar
• McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 107, 1573–1578 (1994).
   PubMedGoogle Scholar
• Ohara T, Goshi S, Taneike I et al. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter 6, 125–129 (2001).
   PubMedGoogle Scholar
• Goddard AF, Jessa MJ, Barrett DA et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111, 358–367 (1996).
   PubMed Web of Science ®Google Scholar
• Sjostrom JE, Larsson H. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild type strain and a urease-deficient mutant. J. Med. Microbiol. 44, 425–433 (1996).
   PubMedGoogle Scholar
• Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 43(Suppl. 1), S56–S60 (1998).
   Web of Science ®Google Scholar
• Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J. Biol. Med. 69, 301–316 (1996).
   PubMedGoogle Scholar
• Sidebotham RL, Worku ML, Karim QN, Dhir NK, Baron JH. How Helicobacter pylori urease may affect external pH and influence growth and motility in the mucus environment: evidence from in vitro studies. Eur. J. Gastroenterol. Hepatol. 15, 395–401 (2003).
   PubMedGoogle Scholar
• Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1, 138–144 (1996).
   PubMedGoogle Scholar
• Miwa H, Ohkura R, Murai T et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection – comparison with omeprazole and lansoprazole. Aliment. Pharmacol. Ther. 13, 741–746 (1999).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bayerdorffer E, Diete U et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther. 13, 703–712 (1999).
   PubMed Web of Science ®Google Scholar
• Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116, 248–253 (1999).
   PubMed Web of Science ®Google Scholar
• Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment. Pharmacol. Ther. 15, 1023–1029 (2001).
   PubMedGoogle Scholar
• Isomoto H, Furusu H, Morikawa T et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 14, 1619–1623 (2000).
   PubMedGoogle Scholar
• Kihira K, Satoh K, Saifuku K et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 14, 1083–1087 (2000).
   PubMed Web of Science ®Google Scholar
• Wong BC, Wong WM, Yee YK et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 15, 1959–1965 (2001).
   PubMed Web of Science ®Google Scholar
• Inaba T, Mizuno M, Kawai K et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J. Gastroenterol. Hepatol. 17, 748–753 (2002).
   PubMed Web of Science ®Google Scholar
• Gambaro C, Bilardi C, Dulbecco P et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig. Liver Dis. 35, 763–767 (2003).
   PubMedGoogle Scholar
• Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment. Pharmacol. Ther. 17, 1065–1074 (2003).
   PubMedGoogle Scholar
• Kositchaiwat C, Ovartlarnporn B, Kachintorn U, Atisook K. Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 18, 1017–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 17, 259–264 (2003).
   PubMed Web of Science ®Google Scholar
• Yang KC, Wang GM, Chen JH, Chen TJ, Lee SC. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. J. Formos. Med. Assoc. 102, 857–862 (2003).
   PubMedGoogle Scholar
• Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther. 20, 99–107 (2004).
   PubMed Web of Science ®Google Scholar
• Wang HH, Chou JW, Liao KF et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World J. Gastroenterol. 11, 1680–1684 (2005).
   PubMedGoogle Scholar
• He XX, Zhao YH, Hao YT. Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese. Zhonghua Nei Ke Za Zhi 43, 13–15 (2004).
   PubMedGoogle Scholar
• Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 16, 1811–1817 (2002).
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Takashima M et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11, 341–348 (2001).
   PubMedGoogle Scholar
• Lee SB, Park SJ, Ryu JK et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. Korean J. Gastroenterol. 42, 468–475 (2003).
   PubMedGoogle Scholar
• Miki I, Aoyama N, Sakai T et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur. J. Gastroenterol. Hepatol. 15, 27–33 (2003).
   PubMed Web of Science ®Google Scholar
• Dojo M, Azuma T, Saito T et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig. Liver Dis. 33, 671–675 (2001).
   PubMedGoogle Scholar
• Hokari K, Sugiyama T, Kato M et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment. Pharmacol. Ther. 15, 1479–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Miyoshi M, Mizuno M, Ishiki K et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J. Gastroenterol. Hepatol. 16, 723–728 (2001).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 17, 751–764 (2003).
   PubMedGoogle Scholar
• Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment. Pharmacol. Ther. 16, 1149–1156 (2002).
   PubMed Web of Science ®Google Scholar
• Miwa H, Yamada T, Sato K et al. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig. Dis. Sci. 45, 77–82 (2000).
   PubMed Web of Science ®Google Scholar
• Mario FD, Dal Bo N, Aragona G et al. Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages. J. Gastroenterol. Hepatol. 18, 783–786 (2003).
   PubMedGoogle Scholar
• Cammarota G, Cianci R, Cannizzaro O et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 14, 1339–1343 (2000).
   PubMed Web of Science ®Google Scholar
• Iacopini F, Crispino P, Paoluzi OA et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig. Liver Dis. 37, 571–576 (2005).
   PubMedGoogle Scholar
• Sharara AI, Chaar HF, Racoubian E et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 9, 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. 45, 68–76 (2000).
   PubMed Web of Science ®Google Scholar
• van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol. 94, 1751–1759 (1999).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gonzalez L, Calvet X et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 14, 1319–1328 (2000).
   PubMed Web of Science ®Google Scholar
• Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy 23, S74–S80 (2003).
   Google Scholar
• Sharara AI, Chaar HF, Aoun E. Gatifloxacin-based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication. 69th annual scientific meeting of the American College of Gastroenterology. FL, USA (2004).
   Google Scholar